Meropenem Sun

Meropenem, the active ingredient in Meropenem Sun, is a carbapenem presented as a sterile powder for intravenous use. It treats severe bacterial infections such as complicated intra‑abdominal infections, complicated urinary tract infections, bacterial meningitis, severe sepsis, and hospital‑acquired pneumonia in hospitalized patients.

GNH USA supplies Meropenem Sun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Meropenem is a broad‑spectrum carbapenem antibiotic used for serious infections caused by Gram‑negative and Gram‑positive bacteria.

- Complicated intra‑abdominal infections: achieves bacterial eradication and clinical cure in patients with severe intra‑abdominal infections. - Complicated urinary tract infections: provides effective treatment of resistant urinary pathogens. - Bacterial meningitis: penetrates the cerebrospinal fluid to eradicate meningitis‑causing organisms. - Severe sepsis: rapidly reduces bacterial load in systemic infection. - Hospital‑acquired pneumonia: treats ventilator‑associated and other nosocomial pneumonias.

Adverse reactions may occur with meropenem therapy. Most are mild and reversible, but serious events require prompt medical attention.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Rash: erythematous skin eruption. - Headache: transient and usually resolves. - Infusion site reactions: pain, erythema, or phlebitis. - Elevated liver enzymes: mild transaminase increase.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disorders. - Clostridioides difficile‑associated diarrhea: severe colitis risk. - Anaphylaxis: acute hypersensitivity reaction. - Severe neutropenia: marked reduction in white blood cells. - Renal toxicity: acute kidney injury in susceptible individuals. - Hepatic failure: rare but possible liver dysfunction.

Careful assessment and monitoring are required when using meropenem. - Renal function: adjust dose in patients with impaired renal clearance. - Hepatic function: monitor liver enzymes during prolonged therapy. - Seizure risk: avoid in patients with a history of seizures or CNS disorders. - Valproic acid co‑administration: may increase seizure frequency. - Pregnancy: safety unknown; use only if benefits outweigh potential risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Meropenem may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Valproic acid: increased risk of seizures. - Aminoglycosides: additive nephrotoxicity. - Loop diuretics: may exacerbate renal impairment.

Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of INR, monitor coagulation. - Probenecid: reduces renal clearance of meropenem, adjust dose if needed. - Oral contraceptives: possible reduction in contraceptive effectiveness, advise alternative methods.